EA200501425A1 - Арилвинилазациклоалкановые соединения и способы их получения и применения - Google Patents
Арилвинилазациклоалкановые соединения и способы их получения и примененияInfo
- Publication number
- EA200501425A1 EA200501425A1 EA200501425A EA200501425A EA200501425A1 EA 200501425 A1 EA200501425 A1 EA 200501425A1 EA 200501425 A EA200501425 A EA 200501425A EA 200501425 A EA200501425 A EA 200501425A EA 200501425 A1 EA200501425 A1 EA 200501425A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disorders
- compounds
- disease
- central nervous
- nervous system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Описываются новые винилазациклоалкановые соединения формулы (I). Соединения представляют лиганды различных nAChR. Соединения и их фармацевтически приемлемые соли могут применяться для приготовления фармацевтических композиций и/или медикаментов, предназначенных для профилактики или лечения расстройств, связанных с дисфункцией nAChR, в частности в центральной нервной системе или желудочно-кишечной системе. Примеры типов расстройств, которые могут лечиться, включают нейродегенеративные расстройства, включая расстройства центральной нервной системы, такие как болезнь Альцгеймера, когнитивные расстройства, двигательные расстройства, такие как болезнь Паркинсона, лекарственная зависимость, нарушения поведения, и воспалительные расстройства в желудочно-кишечной системе. Соединения также могут служить в качестве анальгетиков при лечении острой, хронической или рецидивной боли.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/379,868 US7098331B2 (en) | 2003-03-05 | 2003-03-05 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
PCT/US2004/006530 WO2004078752A1 (en) | 2003-03-05 | 2004-03-04 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200501425A1 true EA200501425A1 (ru) | 2006-02-24 |
EA010870B1 EA010870B1 (ru) | 2008-12-30 |
Family
ID=32926772
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200501425A EA010870B1 (ru) | 2003-03-05 | 2004-03-04 | Арилвинилазациклоалкановые соединения и способы их получения и применения |
EA200900706A EA019240B1 (ru) | 2003-03-05 | 2004-03-04 | Арилвинилазациклоалкановые соединения и способы их получения и применения |
EA200801764A EA014714B1 (ru) | 2003-03-05 | 2004-03-04 | Арилвинилазациклоалкановое соединение, фармацевтическая композиция на его основе и способы его применения |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200900706A EA019240B1 (ru) | 2003-03-05 | 2004-03-04 | Арилвинилазациклоалкановые соединения и способы их получения и применения |
EA200801764A EA014714B1 (ru) | 2003-03-05 | 2004-03-04 | Арилвинилазациклоалкановое соединение, фармацевтическая композиция на его основе и способы его применения |
Country Status (32)
Country | Link |
---|---|
US (8) | US7098331B2 (ru) |
EP (3) | EP1601670B1 (ru) |
JP (3) | JP4663627B2 (ru) |
KR (4) | KR20120014236A (ru) |
CN (3) | CN101550132B (ru) |
AR (3) | AR043469A1 (ru) |
AT (3) | ATE394394T1 (ru) |
AU (3) | AU2004217903B2 (ru) |
BR (1) | BRPI0409576A (ru) |
CA (1) | CA2516514C (ru) |
CL (1) | CL2004000452A1 (ru) |
CY (2) | CY1110391T1 (ru) |
DE (2) | DE602004013553D1 (ru) |
DK (2) | DK1601670T3 (ru) |
EA (3) | EA010870B1 (ru) |
ES (3) | ES2385941T3 (ru) |
GT (1) | GT200400033A (ru) |
HK (3) | HK1084949A1 (ru) |
IL (3) | IL170155A (ru) |
JO (1) | JO2488B1 (ru) |
MX (1) | MXPA05009386A (ru) |
NO (3) | NO331920B1 (ru) |
NZ (1) | NZ541795A (ru) |
PA (1) | PA8597201A1 (ru) |
PE (1) | PE20040930A1 (ru) |
PL (5) | PL1601670T3 (ru) |
PT (2) | PT2085395E (ru) |
SI (2) | SI2085395T1 (ru) |
TW (3) | TWI339662B (ru) |
UY (1) | UY28218A1 (ru) |
WO (1) | WO2004078752A1 (ru) |
ZA (1) | ZA200506790B (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7098331B2 (en) * | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
FR2896800B1 (fr) * | 2006-01-30 | 2008-04-11 | Servier Lab | Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
WO2008157365A2 (en) * | 2007-06-15 | 2008-12-24 | Targacept, Inc. | Vinylazacycloalkanes for treating neuropathic pain |
US20110098312A1 (en) * | 2008-05-12 | 2011-04-28 | Targacept ,Inc | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
TW201024283A (en) * | 2008-12-01 | 2010-07-01 | Targacept Inc | Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine |
MX2011005611A (es) * | 2008-12-01 | 2011-09-15 | Targacept Inc | Sintesis y formas de sales novedosas de (r)-5-((e)-2-(pirrolidin-3 -il-vinil)pirimidina. |
US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
JP2012530707A (ja) * | 2009-06-17 | 2012-12-06 | ターガセプト,インコーポレイテッド | 神経性ニコチン受容体リガンドによるl−ドーパ誘発性ジスキネジアの回復 |
KR20120120190A (ko) | 2009-12-07 | 2012-11-01 | 타가셉트 인코포레이티드 | 신경원성 니코틴 아세틸콜린 수용체 리간드인 3,6?디아자비시클로[3.1.1]헵탄 |
CN102858342B (zh) * | 2010-03-11 | 2014-12-10 | 塔加西普特公司 | 用于便秘的芳基乙烯基氮杂环烷烃化合物 |
US20110274628A1 (en) * | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
US20140081714A1 (en) * | 2012-09-19 | 2014-03-20 | Salesforce.Com, Inc. | Systems and methods of rewarding users in an on-demand system |
US20140278929A1 (en) * | 2013-03-15 | 2014-09-18 | Yahoo! Inc. | System and method identifying opportunities for advertising entities based on user goal achievement |
TWI790997B (zh) | 2016-04-07 | 2023-02-01 | 美商奧伊斯特普安生物製藥公司 | 醫療調配物用於治療眼部病狀之用途 |
KR101848601B1 (ko) * | 2016-07-27 | 2018-04-12 | 송기봉 | 일회용 위생 티슈 |
EP3820443A1 (en) | 2018-07-10 | 2021-05-19 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
WO2020014217A1 (en) | 2018-07-10 | 2020-01-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
WO2021222230A1 (en) | 2020-04-28 | 2021-11-04 | Oyster Point Pharma, Inc. | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989000158A1 (en) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
US4922901A (en) * | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
US5187166A (en) * | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
US5852041A (en) * | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
IT1274018B (it) * | 1994-02-23 | 1997-07-14 | Riace Ets | Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
US5604231A (en) * | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
US5663356A (en) * | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
US6437138B1 (en) * | 1996-06-06 | 2002-08-20 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
US5629325A (en) | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
RU2205179C2 (ru) | 1997-10-27 | 2003-05-27 | НьюроСёрч А/С | Производное гомопиперазина и фармацевтическая композиция |
WO2000075110A1 (en) | 1999-06-07 | 2000-12-14 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
MXPA02002115A (es) | 1999-09-14 | 2002-10-31 | Abbott Lab | Compuestos de eter 3-pirrolidiniloxi-3'-piridilico, utiles para controlar la transmision sinaptica quimica. . |
JP2003513054A (ja) | 1999-11-01 | 2003-04-08 | ターガセプト,インコーポレイテッド | アリールオレフィンアザ環式化合物及びアリールアセチレンアザ環式化合物、それらを含有する薬剤組成物、及び、ニコチンコリン作動性受容体の阻害薬としてのそれらの使用 |
US6624167B1 (en) * | 2000-08-04 | 2003-09-23 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6881738B2 (en) | 2001-07-19 | 2005-04-19 | Medical College Of Georgia Research Institute | Analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders |
US7098331B2 (en) * | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
-
2003
- 2003-03-05 US US10/379,868 patent/US7098331B2/en not_active Expired - Lifetime
-
2004
- 2004-02-10 TW TW093103017A patent/TWI339662B/zh not_active IP Right Cessation
- 2004-02-10 TW TW098105931A patent/TWI377204B/zh not_active IP Right Cessation
- 2004-02-10 TW TW098105932A patent/TW200927746A/zh unknown
- 2004-03-02 PE PE2004000228A patent/PE20040930A1/es not_active Application Discontinuation
- 2004-03-04 AT AT04717398T patent/ATE394394T1/de active
- 2004-03-04 JP JP2006509059A patent/JP4663627B2/ja not_active Expired - Fee Related
- 2004-03-04 EP EP04717398A patent/EP1601670B1/en not_active Expired - Lifetime
- 2004-03-04 AR ARP040100690A patent/AR043469A1/es not_active Application Discontinuation
- 2004-03-04 DE DE602004013553T patent/DE602004013553D1/de not_active Expired - Lifetime
- 2004-03-04 CN CN2009100048828A patent/CN101550132B/zh not_active Expired - Fee Related
- 2004-03-04 SI SI200431638T patent/SI2085395T1/sl unknown
- 2004-03-04 CN CNB2004800060242A patent/CN100526308C/zh not_active Expired - Lifetime
- 2004-03-04 DK DK04717398T patent/DK1601670T3/da active
- 2004-03-04 ES ES09075124T patent/ES2385941T3/es not_active Expired - Lifetime
- 2004-03-04 EP EP08075106A patent/EP1947100B1/en not_active Expired - Lifetime
- 2004-03-04 UY UY28218A patent/UY28218A1/es not_active Application Discontinuation
- 2004-03-04 BR BRPI0409576-6A patent/BRPI0409576A/pt not_active IP Right Cessation
- 2004-03-04 EA EA200501425A patent/EA010870B1/ru active IP Right Revival
- 2004-03-04 PL PL04717398T patent/PL1601670T3/pl unknown
- 2004-03-04 ES ES08075106T patent/ES2389106T3/es not_active Expired - Lifetime
- 2004-03-04 DK DK09075124.9T patent/DK2085395T3/da active
- 2004-03-04 AT AT09075124T patent/ATE496046T1/de active
- 2004-03-04 CN CNA2008100917335A patent/CN101255155A/zh active Pending
- 2004-03-04 EP EP09075124A patent/EP2085395B1/en not_active Expired - Lifetime
- 2004-03-04 KR KR1020127001576A patent/KR20120014236A/ko not_active Application Discontinuation
- 2004-03-04 CA CA2516514A patent/CA2516514C/en not_active Expired - Lifetime
- 2004-03-04 KR KR1020057016343A patent/KR101185541B1/ko not_active IP Right Cessation
- 2004-03-04 KR KR1020097002098A patent/KR101018083B1/ko not_active IP Right Cessation
- 2004-03-04 PL PL09075124T patent/PL2085395T3/pl unknown
- 2004-03-04 PA PA20048597201A patent/PA8597201A1/es unknown
- 2004-03-04 EA EA200900706A patent/EA019240B1/ru not_active IP Right Cessation
- 2004-03-04 NZ NZ541795A patent/NZ541795A/en not_active IP Right Cessation
- 2004-03-04 AT AT08075106T patent/ATE517893T1/de not_active IP Right Cessation
- 2004-03-04 DE DE602004031165T patent/DE602004031165D1/de not_active Expired - Lifetime
- 2004-03-04 AU AU2004217903A patent/AU2004217903B2/en not_active Ceased
- 2004-03-04 PL PL394604A patent/PL215059B1/pl unknown
- 2004-03-04 WO PCT/US2004/006530 patent/WO2004078752A1/en active Application Filing
- 2004-03-04 PL PL394600A patent/PL394600A1/pl unknown
- 2004-03-04 JO JO200422A patent/JO2488B1/en active
- 2004-03-04 EA EA200801764A patent/EA014714B1/ru not_active IP Right Cessation
- 2004-03-04 KR KR1020097002099A patent/KR100953150B1/ko not_active IP Right Cessation
- 2004-03-04 PL PL378415A patent/PL216979B1/pl unknown
- 2004-03-04 PT PT09075124T patent/PT2085395E/pt unknown
- 2004-03-04 ES ES04717398T patent/ES2309507T3/es not_active Expired - Lifetime
- 2004-03-04 SI SI200430775T patent/SI1601670T1/sl unknown
- 2004-03-04 PT PT04717398T patent/PT1601670E/pt unknown
- 2004-03-04 GT GT200400033A patent/GT200400033A/es unknown
- 2004-03-04 MX MXPA05009386A patent/MXPA05009386A/es active IP Right Grant
- 2004-03-08 CL CL200400452A patent/CL2004000452A1/es unknown
-
2005
- 2005-08-08 IL IL170155A patent/IL170155A/en active IP Right Grant
- 2005-08-17 US US11/206,243 patent/US20060094732A1/en not_active Abandoned
- 2005-08-24 ZA ZA200506790A patent/ZA200506790B/xx unknown
- 2005-09-05 NO NO20054120A patent/NO331920B1/no not_active IP Right Cessation
-
2006
- 2006-05-26 HK HK06106130A patent/HK1084949A1/xx not_active IP Right Cessation
-
2008
- 2008-08-06 CY CY20081100831T patent/CY1110391T1/el unknown
- 2008-08-07 US US12/187,584 patent/US7714001B2/en not_active Expired - Lifetime
- 2008-10-29 HK HK09109159.9A patent/HK1130254A1/xx not_active IP Right Cessation
- 2008-10-29 HK HK08111897.3A patent/HK1116800A1/xx not_active IP Right Cessation
- 2008-12-17 AU AU2008258188A patent/AU2008258188B2/en not_active Ceased
- 2008-12-17 AU AU2008258187A patent/AU2008258187B2/en not_active Ceased
-
2009
- 2009-01-05 US US12/348,605 patent/US8063068B2/en not_active Expired - Lifetime
- 2009-02-05 AR ARP090100389A patent/AR070570A2/es not_active Application Discontinuation
- 2009-02-05 AR ARP090100388A patent/AR070569A2/es not_active Application Discontinuation
- 2009-04-05 IL IL197889A patent/IL197889A/en active IP Right Grant
- 2009-04-05 IL IL197890A patent/IL197890A/en active IP Right Grant
- 2009-05-14 NO NO20091888A patent/NO332293B1/no not_active IP Right Cessation
- 2009-06-09 NO NO20092231A patent/NO20092231L/no unknown
- 2009-07-31 JP JP2009178897A patent/JP5537085B2/ja not_active Expired - Lifetime
- 2009-07-31 JP JP2009178896A patent/JP5537084B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-06 US US12/683,106 patent/US8067443B2/en not_active Expired - Fee Related
-
2011
- 2011-02-24 US US13/033,719 patent/US8633222B2/en not_active Expired - Lifetime
- 2011-04-05 CY CY20111100351T patent/CY1111615T1/el unknown
-
2013
- 2013-12-17 US US14/108,918 patent/US20140107164A1/en not_active Abandoned
-
2015
- 2015-02-24 US US14/629,517 patent/US20150164894A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200501425A1 (ru) | Арилвинилазациклоалкановые соединения и способы их получения и применения | |
IL267381A (en) | A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders | |
BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
ATE452652T1 (de) | Behandlung neurologischer und neuropsychiatrischer erkrankungen mit botulinumtoxin | |
HRP20090058A2 (en) | Prodrugs of excitatory amino acids | |
PT1448564E (pt) | Composto do tipo indolizina substituidos e metodos de utilizacao | |
EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
EA200802020A1 (ru) | Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1 | |
TW200502221A (en) | Novel lactams and uses thereof | |
ATE451368T1 (de) | Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems | |
TW200728300A (en) | Therapeutic agents | |
ATE285773T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
TW200510331A (en) | Heteroaryl-substituted imidazole derivatives | |
EA200601580A1 (ru) | Пептид, стимулирующий регенерацию нейронов центральной нервной системы, фармацевтическая композиция на его основе и способ ее применения | |
WO2006138589A3 (en) | Opioid receptor ligands | |
WO2005042561A3 (en) | Neural regeneration peptides and methods of use | |
JP2021105050A (ja) | レビー小体病の治療および/または予防剤 | |
CL2024001452A1 (es) | Formulaciones inyectables e inhalables | |
WO2020106454A3 (en) | Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |
|
NF4A | Restoration of lapsed right to a eurasian patent |
Designated state(s): RU |
|
PC4A | Registration of transfer of a eurasian patent by assignment | ||
TC4A | Change in name of a patent proprietor in a eurasian patent |